PO.IM02.05 · 免疫学
靶向PDE4A消除一个免疫检查点并释放STING驱动的抗肿瘤免疫
Targeting PDE4A ablates an immune checkpoint and unleashes STING-Driven anti-tumor immunity
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
cGAS-STING通路的失调是免疫逃逸的常见机制。在此，我们鉴定磷酸二酯酶4A（PDE4A）为该通路在肿瘤细胞中的关键抑制因子。PDE4A高表达抑制cGAS-STING信号和I型干扰素产生，导致细胞毒性CD8+ T细胞向肿瘤微环境的浸润受损并加速转移。引人注目的是，PDE4A的遗传学敲低及其用罗氟司特（roflumilast）进行的药理学抑制均逆转了这一免疫抑制表型，强效增强了CD8+ T细胞浸润，并抑制了转移进展。我们的发现揭示PDE4A为重新激活抗肿瘤免疫和对抗转移的一个新治疗靶点，提出PDE4A抑制——尤其是使用临床可用药物罗氟司特——作为一种有前景的免疫治疗策略。
查看英文原文 English abstract
Dysregulation of the cGAS-STING pathway is a common mechanism of immune evasion. Here, we identify phosphodiesterase 4A (PDE4A) as a pivotal suppressor of this pathway in tumor cells. High PDE4A expression dampens cGAS-STING signaling and type I interferon production, resulting in impaired infiltration of cytotoxic CD8+ T cells into the tumor microenvironment and accelerated metastasis. Strikingly, both genetic knockdown of PDE4A and its pharmacological inhibition with roflumilast reversed this immune-suppressive phenotype, potently enhanced CD8+ T cell infiltration, and suppressed metastatic progression. Our findings unveil PDE4A as a novel therapeutic target to reactivate anti-tumor immunity and combat metastasis, nominating PDE4A inhibition, particularly with the clinically available agent roflumilast, as a promising immunotherapeutic strategy.
利益披露 Disclosure
R. Xiang, None.